Rajasekhar reddy Alavala

Dr. Rajasekhar reddy Alavala

K L deemed to be University
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
NCNarsaiah Chelimela
Narsaiah Chelimela
Rajasekhar reddy AlavalaRajasekhar reddy Alavala
Rajasekhar reddy Alavala
SSShobha Rani Satla
Shobha Rani Satla

1 September 2013 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Rajasekhar reddy AlavalaRajasekhar reddy Alavala
Rajasekhar reddy Alavala
PDP. Dinesh
P. Dinesh
APA.S. Prabhakar
A.S. Prabhakar
umasankar kulandaiveluumasankar kulandaivelu
umasankar kulandaivelu
BSB. Shireesha
B. Shireesha
MRM. Bhagavan Raju
M. Bhagavan Raju
Curcumin, a natural diaryl heptanoid continues to be used as an alternative medicinal agent in many parts of South East Asia for treatment of many ailments. It can be usually obtained from substituted aryl aldehydes and acetylacetone and this route enables synthesis of a diverse set of curcumin analogues. Numerous analogues have been synthesized and tested by several researchers to investigate their activity against known biological targets and to improve upon the pharmacological and ADME profile by modifying substitutions on aromatic rings, β-diketone moiety and two flanking double bonds conjugated to the β-diketone moiety. Successful synthesis of such derivatives with modifications has resulted in the development of potential anticancer candidates that target various stages in cancer cell growth and development. Based on the evidences in modifications of these three functional elements, we have attempted to summarize the structure activity relationship of molecules which can be further utilized by researchers in medicinal chemistry in exploring the structure of curcumin.

8 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AAAfzal Haq Asif
Afzal Haq Asif
Prasanna Kumar DesuPrasanna Kumar Desu
Prasanna Kumar Desu
Rajasekhar reddy AlavalaRajasekhar reddy Alavala
Rajasekhar reddy Alavala
GRGSN Koteswara Rao
GSN Koteswara Rao
Nagaraja SreeharshaNagaraja Sreeharsha
Nagaraja Sreeharsha
GMGirish Basavarajappa Meravanige
Girish Basavarajappa Meravanige
The purpose of the present research work was to design, optimize, and evaluate fluvastatin-loaded solid lipid nanoparticles (FLV-SLNPs) using 32 factorial design for enhancing the bioavailability. Fluvastatin has several disadvantages, including the low solubility and substantial first-pass metabolism resulting in a low (30%) bioavailability and a short elimination half-life. FLV-SLNPs were prepared using the nano-emulsion technique. For the optimization of the FLV-SLNPs, a total of nine formulations were prepared by varying two independent factors at three levels, using full factorial design. In this design, lipid (A) and surfactant (B) concentrations were chosen as independent factors, whereas entrapment efficiency (Y1) and in-vitro drug release (Y2) were selected as the dependent variables. Additionally, the prepared SLNPs were characterized for X-ray diffraction, Fourier transform-infrared spectroscopy, and differential scanning calorimetry. These studies revealed that there were no interactions between the drug and the selected excipients and the selected formulation components are compatible with the drug. Pharmacokinetic studies in rats confirmed significant improvement in AUC and MRT of SLNPs in comparison with the pure drug indicating the enhanced bioavailability of SLNPs. This study provides a proof-of-concept for the fact that SLNPs can be effectively developed via experimental factorial design, which requires relatively minimal experimentation.

1 July 2021 in Combinatorial Chemistry & High Throughput Screening
Verified
Journal Article
Closed access
PDF file
UGUma Sankar Gorla
Uma Sankar Gorla
KRKoteswara Rao
Koteswara Rao
UKUma Sankar Kulandaivelu
Uma Sankar Kulandaivelu
Rajasekhar reddy AlavalaRajasekhar reddy Alavala
Rajasekhar reddy Alavala
SPSiva Prasad Panda
Siva Prasad Panda
Background: COVID-19 is a pandemic respiratory contagious viral (SARS-CoV-2) disease associated with high morbidity and mortality worldwide. Currently, there are no effective preventive or treatment strategies for COVID-19 and it has been declared as a global health emergency by WHO. In silico molecular docking studies can be useful to predict the binding affinity between the phytocompound and the target protein and play a vital role in finding an inhibitor through structure-based drug design. Objective: In this aspect, our objective was to screen essential flavonoids against possible protein targets such as SARS-CoV-2 spike glycoprotein receptor binding domain (RBD-S) and host Angiotensin Converting Enzyme-2 protease domain (PD-ACE-2) using in silico molecular docking studies. Methods: Approximately 49 flavonoids were identified and were evaluated for their drug-likeness based on Lipinski rule, bioactivity scores, antiviral and toxicity profiles using SwissADME, Molinspiration, PASS and GUSAR online tools. The flavonoids that passed Lipinski rule were subjected to in silico analysis through molecular docking on RBD-S and PD-ACE-2 using Molegro Virtual Docker v6.0. Results: The bioactive flavonoids that showed NIL violations and were found in compliance with Lipinski rule were selected for docking studies. In silico analysis reported that biochanin A and silymarin bind significantly at the active sites of RBD-S and PD-ACE-2 with a MolDock score of -78.41and -121.28 kcal/mol respectively. Bioactivity scores, antiviral potential and toxicity profiles were predicted for the top interacting phytocompounds and substantial relevant data was reported. Conclusion: The current outcomes created a new paradigm for understanding biochanin A and silymarin bioflavonoids as potent inhibitors of RBD-S and PD-ACE-2 targets respectively. Further work can be extended to confirm their therapeutic potential for COVID-19.

30 December 2021 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
BJBikash Ranjan Jena
Bikash Ranjan Jena
SPSiva Prasad Panda
Siva Prasad Panda
umasankar kulandaiveluumasankar kulandaivelu
umasankar kulandaivelu
Rajasekhar reddy AlavalaRajasekhar reddy Alavala
Rajasekhar reddy Alavala
GRGSN Koteswara Rao
GSN Koteswara Rao
DGDebashish Ghose
Debashish Ghose
Abiraterone acetate is a well-known anticancer drug and a steroidal derivative of progesterone for treatment of patients with hormone-refractory prostate cancer. Chemometrics-assisted reverse phase high performance liquid chromatography (RP-HPLC) development of the drug abiraterone acetate has been employed in this study using an analytical quality by design (AQbD) approach. Drug separation was performed using a Princeton Merck-Hibar Purospher STAR (C18, 250 mm × 4.6 mm) i.d., 5 μm particle size) with ultraviolet detection at 235 nm. A Box-Behnken statistical experimental design with response surface methodology was executed for method optimization and desired chromatographic separation from its formulation with a few numbers of experimental trials. The impact of three independent variables, namely, composition of the mobile phase, pH, and flow rate, on response retention time and peak area was studied by constructing an arithmetic model from these variables. Optimized experimental conditions for the proposed work include the mobile phase acetonitrile and phosphate buffer (10 mM KH2PO4) (20:80 %v/v). At the concentration range of 2-100 μg/mL, a linear calibration curve was found. Recovery was performed at three concentrations and was foun to be between 98% and 102%. The 3D response surface curves revealed that mobile phase composition and flow rate were the most substantial critical factors affecting desired responses. An attempt has been made to develop and validate an economical, precise, robust, stability-indicating AQbD-based RP-HPLC method that can be employed successfully for the routine analysis of abiraterone acetate in quality control labs.

10 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MHMichelyne Haroun
Michelyne Haroun
SCSantosh S. Chobe
Santosh S. Chobe
Rajasekhar reddy AlavalaRajasekhar reddy Alavala
Rajasekhar reddy Alavala
SMSavita M. Mathure
Savita M. Mathure
RJRisy Namratha Jamullamudi
Risy Namratha Jamullamudi
Md Khalid AnwerMd Khalid Anwer
Md Khalid Anwer
Considering the importance of benzothiazepine pharmacophore, an attempt was carried out to synthesize novel 1,5-benzothiazepine derivatives using polyethylene glycol-400 (PEG-400)-mediated pathways. Initially, different chalcones were synthesized and then subjected to a cyclization step with benzothiazepine in the presence of bleaching clay and PEG-400. PEG-400-mediated synthesis resulted in a yield of more than 95% in less than an hour of reaction time. Synthesized compounds 2a–2j were investigated for their in vitro cytotoxic activity. Moreover, the same compounds were subjected to systematic in silico screening for the identification of target proteins such as human adenosine kinase, glycogen synthase kinase-3β, and human mitogen-activated protein kinase 1. The compounds showed promising results in cytotoxicity assays; among the tested compounds, 2c showed the most potent cytotoxic activity in the liver cancer cell line Hep G-2, with an IC50 of 3.29 ± 0.15 µM, whereas the standard drug IC50 was 4.68 ± 0.17 µM. In the prostate cancer cell line DU-145, the compounds displayed IC50 ranges of 15.42 ± 0.16 to 41.34 ± 0.12 µM, while the standard drug had an IC50 of 21.96 ± 0.15 µM. In terms of structural insights, the halogenated phenyl substitution on the second position of benzothiazepine was found to significantly improve the biological activity. This characteristic feature is supported by the binding patterns on the selected target proteins in docking simulations. In this study, 1,5-benzothiazepines have been identified as potential anticancer agents which can be further exploited for the development of more potent derivatives.